Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) Debt to Equity (2022 - 2025)

Historic Debt to Equity for Tarsus Pharmaceuticals (TARS) over the last 4 years, with Q3 2025 value amounting to $0.22.

  • Tarsus Pharmaceuticals' Debt to Equity fell 2856.03% to $0.22 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.22, marking a year-over-year decrease of 2856.03%. This contributed to the annual value of $0.32 for FY2024, which is 11137.87% up from last year.
  • Tarsus Pharmaceuticals' Debt to Equity amounted to $0.22 in Q3 2025, which was down 2856.03% from $0.22 recorded in Q2 2025.
  • Over the past 5 years, Tarsus Pharmaceuticals' Debt to Equity peaked at $0.32 during Q4 2024, and registered a low of $0.09 during Q2 2022.
  • Moreover, its 4-year median value for Debt to Equity was $0.15 (2023), whereas its average is $0.18.
  • Its Debt to Equity has fluctuated over the past 5 years, first surged by 11716.57% in 2024, then crashed by 2856.03% in 2025.
  • Over the past 4 years, Tarsus Pharmaceuticals' Debt to Equity (Quarter) stood at $0.1 in 2022, then skyrocketed by 50.25% to $0.15 in 2023, then soared by 111.38% to $0.32 in 2024, then crashed by 32.58% to $0.22 in 2025.
  • Its Debt to Equity was $0.22 in Q3 2025, compared to $0.22 in Q2 2025 and $0.21 in Q1 2025.